CDK4 and neoplasm: O’Brien et al. [79] show that CDK4/6 inhibitor-resistant xenografts treated with everolimus, an mTOR inhibitor, and fulvestrant have the largest decrease in tumor volume over the course of about 115 days compared to when fulvestrant is paired with either ribociclib or alpelisib.